A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Jan 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Selinexor (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Acronyms SIGN
Sponsors Karyopharm Therapeutics

07 Dec 2019 Results published in the Gynecologic Oncology
31 Mar 2017 Status changed from active, no longer recruiting to completed.
11 Oct 2016 Results assessing the efficacy and safety of selinexor in patients with metastatic ovarian, cervical & endometrial cancers presented at the 41st European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com